Monitoring patients taking oral carbonic anhydrase inhibitors

F. T. Fraunfelder; Grover C. Bagby

doi:10.1016/S0002-9394(00)00624-3

Monitoring patients taking oral carbonic anhydrase inhibitors

F. T. Fraunfelder
, Grover C. Bagby

Research output: Contribution to journal › Editorial › peer-review

16 Scopus citations

Abstract

Although no prospective studies have been done and no recommendations can be reasonable evidenced based, we believe that our 'alternative views' are reasonable, taking into account the serious nature of aplastic anemia and its more favorable prognosis when this disorder is treated early. Because aplastic anemia represents only about one half of possible CAI blood dyscrasias alone justifies hematologic screening.

Original language	English (US)
Pages (from-to)	221-223
Number of pages	3
Journal	American journal of ophthalmology
Volume	130
Issue number	2
DOIs	https://doi.org/10.1016/S0002-9394(00)00624-3
State	Published - 2000

Funding

This study was funded, in part, by an unrestricted grant from Research to Prevent Blindness, New York, NY.

Funders
Research to Prevent Blindness

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S0002-9394(00)00624-3

Cite this

@article{e48643b36a9d458fb6795dcb26f23b4b,

title = "Monitoring patients taking oral carbonic anhydrase inhibitors",

abstract = "Although no prospective studies have been done and no recommendations can be reasonable evidenced based, we believe that our 'alternative views' are reasonable, taking into account the serious nature of aplastic anemia and its more favorable prognosis when this disorder is treated early. Because aplastic anemia represents only about one half of possible CAI blood dyscrasias alone justifies hematologic screening.",

author = "Fraunfelder, \{F. T.\} and Bagby, \{Grover C.\}",

note = "Funding Information: This study was funded, in part, by an unrestricted grant from Research to Prevent Blindness, New York, NY. ",

year = "2000",

doi = "10.1016/S0002-9394(00)00624-3",

language = "English (US)",

volume = "130",

pages = "221--223",

journal = "American journal of ophthalmology",

issn = "0002-9394",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - Monitoring patients taking oral carbonic anhydrase inhibitors

AU - Fraunfelder, F. T.

AU - Bagby, Grover C.

N1 - Funding Information: This study was funded, in part, by an unrestricted grant from Research to Prevent Blindness, New York, NY.

PY - 2000

Y1 - 2000

N2 - Although no prospective studies have been done and no recommendations can be reasonable evidenced based, we believe that our 'alternative views' are reasonable, taking into account the serious nature of aplastic anemia and its more favorable prognosis when this disorder is treated early. Because aplastic anemia represents only about one half of possible CAI blood dyscrasias alone justifies hematologic screening.

AB - Although no prospective studies have been done and no recommendations can be reasonable evidenced based, we believe that our 'alternative views' are reasonable, taking into account the serious nature of aplastic anemia and its more favorable prognosis when this disorder is treated early. Because aplastic anemia represents only about one half of possible CAI blood dyscrasias alone justifies hematologic screening.

UR - https://www.scopus.com/pages/publications/0033833803

UR - https://www.scopus.com/pages/publications/0033833803#tab=citedBy

U2 - 10.1016/S0002-9394(00)00624-3

DO - 10.1016/S0002-9394(00)00624-3

M3 - Editorial

C2 - 11004298

AN - SCOPUS:0033833803

SN - 0002-9394

VL - 130

SP - 221

EP - 223

JO - American journal of ophthalmology

JF - American journal of ophthalmology

IS - 2

ER -

Monitoring patients taking oral carbonic anhydrase inhibitors

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this